Search results for "AGENTS"

showing 10 items of 7330 documents

Asthmatics with high levels of serum surfactant protein D have more severe disease.

2016

Pulmonary surfactant is a mixture of lipids and surfactant-specific proteins that covers the alveolar surface, as well as the terminal conducting airways, lowering the surface tension at the air–liquid interface during breathing. The involvement of pulmonary surfactant in the pathophysiology of asthma has been suggested. An interesting working hypothesis is that the surface tension of the peripheral airways is altered in asthma, because the inflammatory process affects the structure and function of surfactant, leading to excessive airway narrowing and features of air trapping. We explored whether serum levels of surfactant protein D (SP-D) in asthmatics are related to the severity of the di…

0301 basic medicinePulmonary and Respiratory MedicineAdultMalesurfactantStatistics as TopicSevere diseasemacromolecular substancesSettore MED/10 - Malattie Dell'Apparato RespiratorioSeverity of Illness Index03 medical and health sciences0302 clinical medicineSeverity of illnessMedicineHumansAnti-Asthmatic Agentsbusiness.industrySmall airwaysSurfactant protein DReproducibility of Resultsrespiratory systemMiddle AgedPulmonary Surfactant-Associated Protein DAsthmaRespiratory Function Tests030104 developmental biology030228 respiratory systemImmunologyBiomarker (medicine)FemalebusinessBiomarkersThe European respiratory journal
researchProduct

Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009-2016

2018

In Italy, rifampicin-resistant and MDR-TB were high in foreign-born persons, but decreased from 2009 to 2016

0301 basic medicinePulmonary and Respiratory MedicineExtensively Drug-Resistant TuberculosisAntitubercular AgentsEmigrants and ImmigrantsAntitubercular Agents; Emigrants and Immigrants; Extensively Drug-Resistant Tuberculosis; Humans; Italy; Mycobacterium tuberculosis; Rifampin; Tuberculosis Multidrug-ResistantMycobacterium tuberculosis03 medical and health sciences0302 clinical medicineTuberculosis Multidrug-Resistantpolycyclic compoundsmedicineTuberculosisHumansbiologybusiness.industryExtensively drug-resistant tuberculosisMycobacterium tuberculosisMultidrug-Resistantmedicine.diseasebiology.organism_classificationVirology030104 developmental biology030228 respiratory systemItalyRifampinbusinessRifampicinmedicine.drug
researchProduct

Metabolic and inflammatory reprogramming of macrophages by ONC201 translates in a pro-inflammatory environment even in presence of glioblastoma cells

2020

Tumor-associated macrophages facilitate tumor progression and resistance to therapy. Their capacity for metabolic and inflammatory reprogramming represents an attractive therapeutic target. ONC201/TIC10 is an anticancer molecule that antagonizes the dopamine receptor D2 and affects mitochondria integrity in tumor cells. We examined whether ONC201 induces a metabolic and pro-inflammatory switch in primary human monocyte-derived macrophages that reactivates their antitumor activities, thus enhancing the onco-toxicity of ONC201. Contrary to glioblastoma cells, macrophages exhibited a low ratio of dopamine receptors D2/D5 gene expression and were resistant to ONC201 cytotoxicity. Macrophages re…

0301 basic medicinePyridinesImmunology610 MedizinGlutamic AcidAntineoplastic AgentsMitochondrionBiology570 Life sciences03 medical and health sciences0302 clinical medicineImmune systemCell Line TumorDopamine receptor D2610 Medical sciencesTumor MicroenvironmentHumansImmunology and AllergyMacrophageReceptors Dopamine D5Tumor microenvironmentReceptors Dopamine D2MacrophagesImidazolesMitochondriaCell biologyGene Expression Regulation NeoplasticPyrimidines030104 developmental biologyDrug Resistance NeoplasmTumor progressionDopamine receptorEnergy MetabolismGlioblastomaReprogrammingTranscription Factor CHOPSignal Transduction030215 immunology570 Biowissenschaften
researchProduct

Recent advances on CDK inhibitors: An insight by means of in silico methods

2017

The cyclin dependent kinases (CDKs) are a small family of serine/threonine protein kinases that can act as a potential therapeutic target in several proliferative diseases, including cancer. This short review is a survey on the more recent research progresses in the field achieved by using in silico methods. All the "armamentarium" available to the medicinal chemists (docking protocols and molecular dynamics, fragment-based, de novo design, virtual screening, and QSAR) has been employed to the discovery of new, potent, and selective inhibitors of cyclin dependent kinases. The results cited herein can be useful to understand the nature of the inhibitor-target interactions, and furnish an ins…

0301 basic medicineQuantitative structure–activity relationshipMolecular dynamicIn silicoCDKQuantitative Structure-Activity RelationshipAntineoplastic AgentsComputational biologyMolecular Dynamics SimulationBioinformatics01 natural sciencesSerine03 medical and health sciencesCyclin-dependent kinaseNeoplasmsDrug DiscoveryAnimalsHumansProtein Kinase InhibitorsPharmacologyVirtual screeningHVTSbiologyChemistryKinaseQSARDrug Discovery3003 Pharmaceutical ScienceOrganic ChemistryGeneral MedicineCyclin-Dependent Kinases0104 chemical sciencesMolecular Docking Simulation010404 medicinal & biomolecular chemistry030104 developmental biologyDocking (molecular)Drug Designbiology.proteinComputer-Aided DesignIn silico methodMolecular modelling
researchProduct

Molecular topology: A new strategy for antimicrobial resistance control

2017

The control of antimicrobial resistance (AMR) seems to have come to an impasse. The use and abuse of antibacterial drugs has had major consequences on the genetic mutability of both pathogenic and nonpathogenic microorganisms, leading to the development of new highly resistant strains. Because of the complexity of this situation, an in silico strategy based on QSAR molecular topology was devised to identify synthetic molecules as antimicrobial agents not susceptible to one or several mechanisms of resistance such as: biofilms formation (BF), ionophore (IA) activity, epimerase (EI) activity or SOS system (RecA inhibition). After selecting a group of 19 compounds, five of them showed signific…

0301 basic medicineQuantitative structure–activity relationshipStaphylococcusIn silico030106 microbiologyMicrobial Sensitivity Testsmedicine.disease_causeMicrobiologyStructure-Activity Relationship03 medical and health sciencesAntibiotic resistanceDrug Resistance BacterialDrug DiscoveryEnterococcus faecalisEscherichia colimedicineEscherichia coliPharmacologyVirtual screeningDose-Response Relationship DrugMolecular StructureChemistryOrganic ChemistryBiofilmGeneral MedicineAntimicrobialAnti-Bacterial Agents030104 developmental biologyBiofilmsRegression AnalysisStaphylococcusEuropean Journal of Medicinal Chemistry
researchProduct

Transcription factor NRF2 as a therapeutic target for chronic diseases: a systems medicine approach

2018

Systems medicine has a mechanism-based rather than a symptom- or organ-based approach to disease and identifies therapeutic targets in a nonhypothesis-driven manner. In this work, we apply this to transcription factor nuclear factor (erythroid-derived 2)-like 2 (NRF2) by cross-validating its position in a protein-protein interaction network (the NRF2 interactome) functionally linked to cytoprotection in low-grade stress, chronic inflammation, metabolic alterations, and reactive oxygen species formation. Multiscale network analysis of these molecular profiles suggests alterations of NRF2 expression and activity as a common mechanism in a subnetwork of diseases (the NRF2 diseasome). This netw…

0301 basic medicineRMSystems AnalysisNF-E2-Related Factor 2MedicinaNF-KAPPA-BAnti-Inflammatory AgentsTYPE-2 DIABETES-MELLITUSGENE PROMOTER POLYMORPHISMDiseaseComputational biologyInteractomeenvironment and public healthGLYCOGEN-SYNTHASE KINASETUMOR-SUPPRESSOR PTENNRF203 medical and health sciencesDrug DiscoveryAnimalsHumansTherapeutic targetsMedicineMolecular Targeted TherapyBardoxolone methylPLACEBO-CONTROLLED PHASE-3PharmacologyMechanism (biology)Drug discoverybusiness.industryDrug RepositioningRChronic inflammationrespiratory systemHEME OXYGENASE 1PROTEIN-PROTEIN INTERACTION3. Good healthSystems medicineDrug repositioning030104 developmental biologyDrug developmentEXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITISChronic DiseaseSystems medicineMolecular MedicineFUMARIC-ACID ESTERSbusiness
researchProduct

Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP)

2021

Atherosclerotic cardiovascular disease (ASCVD) and consequent acute coronary syndromes (ACS) are substantial contributors to morbidity and mortality across Europe. Much of these diseases burden is modifiable, in particular by lipid-lowering therapy (LLT). Current guidelines are based on the sound premise that with respect to low density lipoprotein cholesterol (LDL-C), “lower is better for longer”, and the recent data have strongly emphasized the need of also “the earlier the better”. In addition to statins, which have been available for several decades, the availability of ezetimibe and inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) are additional very effective approa…

0301 basic medicineRMmedicine.medical_specialtyCombination therapyPCSK9 inhibitoreffectivenessTreatment goalsLipid-lowering therapy03 medical and health sciences0302 clinical medicineEzetimibemedicineHumansAcute Coronary SyndromeCombination therapyIntensive care medicinePharmacologyStatins.business.industryAtherosclerotic cardiovascular diseaseAnticholesteremic AgentsPCSK9StatinsEffectiveneDisease ManagementAtherosclerosisEzetimibeLipids030104 developmental biologyPCSK9 inhibitors030220 oncology & carcinogenesisPosition paperSafetybusinessVery high riskmedicine.drug
researchProduct

PI3K-driven HER2 expression is a potential therapeutic target in colorectal cancer stem cells

2020

ObjectiveCancer stem cells are responsible for tumour spreading and relapse. Human epidermal growth factor receptor 2 (HER2) expression is a negative prognostic factor in colorectal cancer (CRC) and a potential target in tumours carrying the gene amplification. Our aim was to define the expression of HER2 in colorectal cancer stem cells (CR-CSCs) and its possible role as therapeutic target in CRC resistant to anti- epidermal growth factor receptor (EGFR) therapy.DesignA collection of primary sphere cell cultures obtained from 60 CRC specimens was used to generate CR-CSC mouse avatars to preclinically validate therapeutic options. We also made use of the ChIP-seq analysis for transcriptional…

0301 basic medicineReceptor ErbB-2Colorectal cancerCetuximabcolorectal cancermedicine.disease_cause03 medical and health sciencesAntineoplastic Agents Immunological0302 clinical medicineSettore MED/04 - PATOLOGIA GENERALECancer stem cellstem cellsTumor Cells CulturedmedicineAdjuvant therapyAnimalsHumansEpidermal growth factor receptorProtein kinase BPI3K/AKT/mTOR pathwayPhosphoinositide-3 Kinase InhibitorsMitogen-Activated Protein Kinase Kinasesdrug resistancebiologybusiness.industryGastroenterologyTrastuzumabmedicine.diseaseantibody targeted therapy030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisNeoplastic Stem CellsCancer researchbiology.proteinKRASPhosphatidylinositol 3-KinaseStem cellColorectal Neoplasmsbusiness
researchProduct

The Good and Bad of Nrf2: An Update in Cancer and New Perspectives in COVID-19

2021

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a well-known transcription factor best recognised as one of the main regulators of the oxidative stress response. Beyond playing a crucial role in cell defence by transactivating cytoprotective genes encoding antioxidant and detoxifying enzymes, Nrf2 is also implicated in a wide network regulating anti-inflammatory response and metabolic reprogramming. Such a broad spectrum of actions renders the factor a key regulator of cell fate and a strategic player in the control of cell transformation and response to viral infections. The Nrf2 protective roles in normal cells account for its anti-tumour and anti-viral functions. However, Nrf2 over…

0301 basic medicineRegulatorAnti-Inflammatory AgentsDiseaseReviewenvironment and public healthNF-κBAntioxidantschemistry.chemical_compound0302 clinical medicineSettore BIO/10 - BiochimicaNeoplasmsoxidative stressBiology (General)SpectroscopyGeneral Medicinerespiratory systemComputer Science ApplicationsChemistrycell death030220 oncology & carcinogenesisSignal transductionSignal TransductionQH301-705.5NF-E2-Related Factor 2Context (language use)BiologyCatalysisNrf2Inorganic Chemistry03 medical and health sciencesmedicinecancerAnimalsHumansPhysical and Theoretical ChemistryMolecular BiologyTranscription factorQD1-999Organic ChemistryCancerCOVID-19NF-κBmedicine.diseaseCOVID-19 Drug Treatment030104 developmental biologychemistryinflammationCytokine stormNeuroscienceInternational Journal of Molecular Sciences
researchProduct

Polyvascular disease: A narrative review of current evidence and a consideration of the role of antithrombotic therapy.

2020

Abstract Background and aims Polyvascular disease (PVD) affects approximately 20% of patients with atherosclerosis and is a strong independent risk factor for ischemic outcomes. However, guidelines do not address screening or treatment for PVD, and there have been no PVD-specific trials. We reviewed subgroup analyses of large randomized controlled trials of more intense antithrombotic therapy to determine whether increased intensity of therapy improved ischemic outcomes in patients with PVD. Methods MEDLINE, MEDLINE in-Process, EMBASE, and the Cochrane Library were queried for randomized controlled trials larger than 5000 patients evaluating secondary prevention therapies in patients with c…

0301 basic medicineRelative risk reductionmedicine.medical_specialtyPopulationCoronary Artery Disease030204 cardiovascular system & hematologyCochrane Librarylaw.invention03 medical and health sciencesPeripheral Arterial Disease0302 clinical medicineRandomized controlled trialFibrinolytic AgentslawRisk FactorsInternal medicineAntithromboticmedicineHumansRisk factoreducationeducation.field_of_studybusiness.industryAbsolute risk reductionAtherosclerosis030104 developmental biologyRelative riskCardiology and Cardiovascular MedicinebusinessPlatelet Aggregation InhibitorsAtherosclerosis
researchProduct